Accentia Biopharmaceuticals, Inc. is committed to building significant value for its stockholders through the commercialization of patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications.

Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID®, a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin's lymphoma; Revimmune™, a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase™, a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.

Accentia's interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc., and Accentia also maintains a royalty interest in Biovest's biologic products.

Accentia's interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc., and Accentia also maintains a royalty interest in Biovest's biologic products.

The National Cell Culture Center (a Biovest division) provides expert customized, cell culture services (contract manufacturing) for customers in the public and private sectors.

We manufacture and market advanced hollow fiber technology reactors, which can offer key advantages over stirred-tank and roller-bottle systems by more cost-effectively and efficiently producing biologic drugs and products such as mammalian cells, therapeutic and diagnostic proteins, vaccines and monoclonal antibodies, while offering convenient scalability options to satisfy research, clinical trial and commercial needs.

Changing the World of Cell Culture

The Acusyst™ Line of Advanced Hollow Fiber Bioreactors:

• AutovaxID™ (pdf)
• miniMAX™ (pdf)
• Maximizer™ (pdf)
• Xcellerator™ (pdf)

Analytica International, Inc. is a wholly-owned subsidiary of Accentia which provides a broad range of consulting services to pharmaceutical and biotechnology companies. Analytica's team in New York and Germany includes research professionals at the Master's and Doctoral level in the fields of medicine, epidemiology, biochemistry, statistics, engineering, public health, pharmacy, health economics and business administration.